233 related articles for article (PubMed ID: 38394929)
1. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
Desantis J; Mercorelli B; Celegato M; Croci F; Bazzacco A; Baroni M; Siragusa L; Cruciani G; Loregian A; Goracci L
Eur J Med Chem; 2021 Dec; 226():113814. PubMed ID: 34534839
[TBL] [Abstract][Full Text] [Related]
3. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
4. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
5. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
Zahid S; Ali Y; Rashid S
J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
[TBL] [Abstract][Full Text] [Related]
6. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
7. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2.
Shaheer M; Singh R; Sobhia ME
J Biomol Struct Dyn; 2022; 40(21):10905-10917. PubMed ID: 34328382
[TBL] [Abstract][Full Text] [Related]
8. Use of ionic liquids in amidation reactions for proteolysis targeting chimera synthesis.
Eleuteri M; Desantis J; Cruciani G; Germani R; Goracci L
Org Biomol Chem; 2024 May; 22(17):3477-3489. PubMed ID: 38602033
[TBL] [Abstract][Full Text] [Related]
9. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
Alugubelli YR; Xiao J; Khatua K; Kumar S; Sun L; Ma Y; Ma XR; Vulupala VR; Atla S; Blankenship LR; Coleman D; Xie X; Neuman BW; Liu WR; Xu S
J Med Chem; 2024 Apr; 67(8):6495-6507. PubMed ID: 38608245
[TBL] [Abstract][Full Text] [Related]
10. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
Alugubelli YR; Xiao J; Khatua K; Kumar S; Ma Y; Ma XR; Vulupala VR; Atla SR; Blankenship L; Coleman D; Neuman BW; Liu WR; Xu S
bioRxiv; 2023 Sep; ():. PubMed ID: 37808777
[TBL] [Abstract][Full Text] [Related]
11. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
12. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
13. Development of VHL-recruiting STING PROTACs that suppress innate immunity.
Zhu Z; Johnson RL; Zhang Z; Herring LE; Jiang G; Damania B; James LI; Liu P
Cell Mol Life Sci; 2023 May; 80(6):149. PubMed ID: 37183204
[TBL] [Abstract][Full Text] [Related]
14. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
15. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
16. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
17. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
19. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Schröder M; Renatus M; Liang X; Meili F; Zoller T; Ferrand S; Gauter F; Li X; Sigoillot F; Gleim S; Stachyra TM; Thomas JR; Begue D; Khoshouei M; Lefeuvre P; Andraos-Rey R; Chung B; Ma R; Pinch B; Hofmann A; Schirle M; Schmiedeberg N; Imbach P; Gorses D; Calkins K; Bauer-Probst B; Maschlej M; Niederst M; Maher R; Henault M; Alford J; Ahrne E; Tordella L; Hollingworth G; Thomä NH; Vulpetti A; Radimerski T; Holzer P; Carbonneau S; Thoma CR
Nat Commun; 2024 Jan; 15(1):275. PubMed ID: 38177131
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
